Cencora, Inc. reported a significant increase in its financial performance for the fiscal year ending September 30, 2025, with total revenue reaching $321.3 billion, a 9.3% increase from $294.0 billion in the previous fiscal year. The U.S. Healthcare Solutions segment was the primary driver of this growth, contributing $291.0 billion, up 9.7% from $265.3 billion, largely due to increased sales of specialty products and a notable rise in sales of GLP-1 products, which surged by 26.9% to $7.7 billion. The International Healthcare Solutions segment also saw a revenue increase of 6.1%, totaling $30.4 billion.
The company's gross profit rose by 15.8% to $11.5 billion, primarily attributed to the U.S. Healthcare Solutions segment, which saw a gross profit increase of 23.1% to $7.9 billion. This growth was bolstered by the acquisition of Retina Consultants of America (RCA) in January 2025, which contributed to the overall profitability. However, total operating expenses also increased by 14.4% to $8.8 billion, driven by the RCA acquisition and higher goodwill impairment charges, which amounted to $723.9 million.
Cencora's operational metrics reflected a robust business environment, with a total employee headcount exceeding 51,000 globally, and approximately 41% of employees based in the U.S. The company maintained a diverse customer base, with its top ten customers accounting for approximately 66% of total revenue. Notably, Walgreens and Boots accounted for about 25% of revenue, while Evernorth Health Services contributed 13%. The company also reported a significant increase in accounts receivable, which rose to $25.2 billion, reflecting the growth in sales.
Looking ahead, Cencora anticipates continued revenue growth driven by industry trends, including the increasing utilization of pharmaceuticals, the introduction of new therapies, and the expansion of generic drugs and biosimilars. However, the company also faces challenges such as regulatory pressures, market competition, and potential impacts from ongoing opioid litigation, for which it has accrued a liability of $4.3 billion. The company remains committed to optimizing its operations and enhancing its market position through strategic investments and acquisitions, while also navigating the complexities of the evolving healthcare landscape.
About Cencora, Inc.
Cencora is a leading global pharmaceutical sourcing and distribution company serving healthcare providers and manufacturers. It offers distribution of brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and related services. The company supports patient access, supply chain efficiency, and market development through logistics, consulting, and value-added solutions across the U.S. and international markets, focusing on healthcare providers, biotech firms, and animal health sectors.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.